If anyone is in the camp that suspects the shortin
Post# of 144125
Would shorting keep the market cap of CYDY low to hamper revenue efforts? How about discouraging institutional investors, keeping CYDY off the NASDAQ?
What would this effort cost a big pharma and what would be the ROI? If they spend 200k per business day, it seems that the cost would come in at about 50m annually. This is small potatoes to pay to save billions in potential lost revenue when CYDY gets approved.
All in IMO of course.